Abstract
Background: Patients with AL amyloidosis present sustained paradoxical vasodilation in response to sympathetic stimulation by cold pressor test (CPT). The clinical relevance of this finding is unknown. We investigated the clinical role of CPT induced vascular and hemodynamic responses. Methods: We prospectively recruited 113 treatment-naïve AL amyloidosis patients. High resolution ultrasonography was used to measure the peak percent change of the brachial artery during CPT and 3 minutes after its withdrawal (postCPT), defined as sustained response. Peripheral and aortic (central) systolic (SBP) and diastolic blood pressure (DBP) were measured at the same timepoints before and 12 months after treatment initiation. All-cause and cardiovascular mortality were recorded (median follow-up 26 months). The same tests were performed in ten healthy volunteers. Results: Sustained vasodilation and reductions in central systolic (%CSBP_post) and peripheral diastolic BP were observed in AL as compared to controls (p<0.01 for all) and were associated with all-cause and cardiovascular death after adjustment for disease-related risk factors (p<0.05 for all). %CSBP_post provided incremental value over Mayo stage. Mechanistic analyses revealed associations of %CSBP_post with markers of neurological and cardiac dysfunction and of myocardial infiltration. Longitudinally, at 12 months, %CSBP_post further decreased in patients with earlier poor hematologic response to disease-specific treatment. Conclusions: Using a noninvasive readily available method in treatment-naïve AL amyloidosis patients, sustained reduction of central SBP after sympathetic stimulation was associated with cardiac dysfunction, poor survival and response to treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Authors did not receive any funding for this study
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to the Declaration of Helsinki and all patients provided a written informed consent form for anonymous publication of scientific data. The Ethics Committee of the General Hospital Alexandra, Athens,Greece approved the study protocol.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.